GLP-1 vs. GLP-2 vs. “GLP-3”: What’s the Difference?

A clear guide to metabolic GLP medications, gut-focused GLP-2 peptides, and retatrutide—the investigational triple agonist often called a “GLP-3.”

GLP-1 medications have transformed conversations about weight management, diabetes, appetite, and metabolic health. As the science has advanced, the terminology has become more complicated.

Semaglutide is commonly described as a GLP-1. Tirzepatide is often described as a dual agonist or “GLP-2” in casual weight-loss conversation, even though it does not activate the GLP-2 receptor. Retatrutide is increasingly called a “GLP-3” because it activates three metabolic hormone-receptor pathways.

These shorthand labels can be useful, but they can also create confusion because GLP-2 is already the name of a separate human intestinal hormone. This guide explains both the formal science and the everyday terminology patients are likely to encounter.

Infographic illustrating the differences among GLP-1, GLP-2, and the so-called GLP-3 (retatrutide), highlighting their roles in metabolism, appetite regulation, blood sugar control, intestinal health, and weight management. It explains why retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon, is informally referred to as GLP-3, despite its formal classification.

What Does GLP Mean?

GLP stands for glucagon-like peptide. GLP-1 and GLP-2 are naturally occurring hormones produced when the body processes a larger precursor protein called proglucagon. Although they share an origin, they activate different receptors and perform very different jobs.

The terminology issueIn formal physiology, GLP-2 is a gut-focused hormone. In informal weight-loss language, people sometimes use “GLP-2” to mean a second-generation or dual agonist such as tirzepatide and “GLP-3” to mean a triple agonist such as retatrutide. This article uses those conversational labels only when clearly identified as shorthand.

What Is GLP-1?

GLP-1 is released after eating and helps coordinate glucose control, appetite, and digestion. Pharmaceutical GLP-1 receptor agonists are designed to remain active much longer than the body’s natural hormone.

Supports glucose-dependent insulin secretion

Helps reduce inappropriate glucagon secretion

Slows gastric emptying

Reduces appetite and food intake

Promotes fullness and improved blood-sugar control

Semaglutide: a GLP-1 receptor agonist

Semaglutide selectively activates the GLP-1 receptor. It is used in approved formulations for type 2 diabetes and chronic weight management. Familiar brand names include Ozempic, Wegovy, and Rybelsus.

Tirzepatide: a dual GIP and GLP-1 agonist

Tirzepatide activates both GIP and GLP-1 receptors. Although patients may casually call it a “GLP-2” because it targets two pathways, it does not activate the actual GLP-2 receptor. Its approved brands include Mounjaro and Zepbound.

What Is a “GLP-3”?

In contemporary peptide and weight-management conversation, “GLP-3” is commonly used as shorthand for retatrutide because it activates three hormone-receptor pathways: GIP, GLP-1, and glucagon.

Formal versus familiar wordingRetatrutide can reasonably be introduced to patients as the investigational triple agonist commonly called a “GLP-3.” Its formal scientific classification is a GIP, GLP-1, and glucagon triple hormone-receptor agonist. The number three refers to three receptor targets—not to a separate human receptor literally named GLP-3.

Why Is Retatrutide So Promising?

Retatrutide combines complementary metabolic signals in one weekly molecule. GLP-1 and GIP activity can support appetite regulation, satiety, insulin secretion, and glucose control. Glucagon-receptor activity may contribute additional effects on energy expenditure and fat metabolism. The goal is not merely to suppress appetite, but to influence several aspects of metabolic regulation at once.

Potential and demonstrated benefits of retatrutide

Substantial weight reduction: In Lilly’s Phase 3 TRIUMPH-1 topline results, participants receiving 12 mg lost an average of 28.3% of body weight over 80 weeks; 45.3% achieved at least 30% weight loss.

Improved blood-sugar control: Phase 3 type 2 diabetes results reported average A1C reductions of approximately 1.7 to 2.0 percentage points across studied doses.

Potential benefit for people with diabetes who often lose less weight on anti-obesity medication: In TRIUMPH-2, participants with type 2 diabetes lost up to an average of 20.8% of body weight over 80 weeks.

Reduced liver fat: A Phase 2 substudy in participants with metabolic dysfunction-associated steatotic liver disease found large reductions in liver fat, supporting continued study for fatty-liver-related metabolic disease.

Potential improvement in weight-related joint symptoms: In TRIUMPH-4, participants with obesity and knee osteoarthritis experienced substantial weight loss alongside meaningful improvement in osteoarthritis pain and physical function.

Possible broader cardiometabolic benefits: Improvements in waist circumference, blood pressure, lipids, insulin sensitivity, and cardiovascular or kidney outcomes are of significant interest, although definitive outcome data are still being collected.

What remains unknownRetatrutide remains investigational and is not FDA-approved as of August 2026. Manufacturer-reported Phase 3 topline results are encouraging, but complete peer-reviewed publications, longer-term safety data, cardiovascular-outcome data, and final regulatory review remain important.

Possible adverse effects and limitations

Reported adverse effects have primarily been gastrointestinal, including nausea, diarrhea, vomiting, constipation, and decreased appetite. Some trials have also observed dose-related increases in heart rate. As with other incretin-based therapies, careful dose escalation, patient selection, and monitoring will be important if retatrutide is approved. Investigational products sold outside authorized clinical trials should not be assumed to have verified identity, purity, potency, or sterility.

What Is the Actual GLP-2 Hormone?

GLP-2 is a naturally occurring gut-focused hormone involved in intestinal growth, adaptation, blood flow, barrier function, and nutrient and fluid absorption. It is not primarily an appetite-suppression or weight-loss pathway.

Supports growth and maintenance of the intestinal lining

Promotes intestinal adaptation

Improves nutrient and fluid absorption

Influences intestinal blood flow and motility

Contributes to mucosal barrier function

Which Peptides Are True GLP-2 Analogs?

Teduglutide

Teduglutide is the established FDA-approved GLP-2 analog, marketed as Gattex in the United States. It is approved for adults and children at least one year old with short bowel syndrome who depend on parenteral support. It can improve intestinal absorption and reduce parenteral-support requirements in appropriately selected patients.

Specialized—not general “gut healing”Teduglutide is not approved as a routine wellness treatment for bloating, food sensitivities, irritable bowel syndrome, or nonspecific “leaky gut.” It requires specialized screening and monitoring because it stimulates intestinal growth and can affect fluid balance, obstruction risk, polyps, biliary or pancreatic disease, and absorption of oral medications.

Glepaglutide

Glepaglutide is an investigational long-acting GLP-2 analog developed for short bowel syndrome. It is not FDA-approved.

Apraglutide

Apraglutide is an investigational once-weekly GLP-2 analog being studied for short bowel syndrome with intestinal failure. It is not FDA-approved.

Dapiglutide

Dapiglutide is an investigational dual GLP-1 and GLP-2 receptor agonist that was studied for obesity and metabolic inflammation. Its development program is currently paused.

Side-by-Side Comparison

Category	Receptors	Primary focus	Example	Status
GLP-1	GLP-1	Appetite, glucose, gastric emptying	Semaglutide	Approved for specified indications
Dual agonist (sometimes casually “GLP-2”)	GIP + GLP-1	Metabolic regulation and weight loss	Tirzepatide	Approved for specified indications
“GLP-3” / triple agonist	GIP + GLP-1 + glucagon	Multi-pathway weight and metabolic regulation	Retatrutide	Investigational; not FDA-approved
True GLP-2 agonist	GLP-2	Intestinal adaptation and absorption	Teduglutide	Approved for short bowel syndrome with parenteral-support dependence

Frequently Asked Questions

Is retatrutide considered a GLP-3?

Yes, it is commonly called a “GLP-3” or triple GLP in patient-facing and peptide conversations because it targets three pathways. Formally, it is a GIP, GLP-1, and glucagon triple agonist.

Is retatrutide FDA-approved?

No. As of August 2026, it remains investigational despite positive Phase 3 topline results.

What could make retatrutide different from semaglutide and tirzepatide?

Retatrutide adds glucagon-receptor activity to GIP and GLP-1 activity. This may enhance energy expenditure and fat metabolism while retaining appetite and glucose effects, although its ultimate place in therapy awaits full regulatory review and comparative data.

Is retatrutide a true GLP-2 medication?

No. Retatrutide does not target the GLP-2 receptor. True GLP-2 analogs include teduglutide and investigational compounds such as glepaglutide and apraglutide.

Is teduglutide used for weight loss?

No. Teduglutide is a specialized intestinal-adaptation therapy for short bowel syndrome in patients dependent on parenteral support.

The Bottom Line

Retatrutide is appropriately described in accessible patient education as the investigational triple agonist commonly called a “GLP-3,” provided the article also explains its three actual targets: GIP, GLP-1, and glucagon. Its clinical-trial results suggest the potential for exceptional weight reduction, improved glycemic control, reduced liver fat, and improvement in some obesity-related complications. At the same time, it remains investigational, and its complete long-term benefit-risk profile is still being established.

True GLP-2 therapies belong to a different category centered on intestinal adaptation and absorption. Teduglutide is the best-established example and has a highly specific approved indication.

About Elixir and WellnessAt Elixir and Wellness in Scottsdale, our goal is to help patients understand emerging metabolic and peptide therapies with both scientific accuracy and practical context—including what is approved, what remains investigational, and how receptor activity may relate to individual health goals.

Medical disclaimer: This article is for educational purposes only and does not replace individualized medical evaluation, diagnosis, or treatment. Investigational therapies are not FDA-approved, and clinical status may change over time.

Editorial references

Eli Lilly: TRIUMPH-1 Phase 3 topline results (May 21, 2026).

Eli Lilly: TRIUMPH-2 and TRANSCEND-T2D Phase 3 topline results (2026).

Jastreboff et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine (2023).

Sanyal et al. Retatrutide and liver fat reduction in metabolic dysfunction-associated steatotic liver disease (2024).

GATTEX (teduglutide) U.S. prescribing information.